MANα1‐2MAN decorated liposomes enhance the immunogenicity induced by a DNA vaccine against BoHV‐1

Kornuta, Claudia Alejandra; Bidart, Juan Esteban; Soria, Ivana; Gammella, Mariela; Quattrocchi, Valeria; Pappalardo, Juan Sebastian; Salmaso, Stefano; Torchilin, Vladimir P.; Valenzuela, Felipe Cheuquepán; Hecker, Yanina P.; Moore, D.P.; Zamorano, Patricia; Langellotti, Cecilia

doi:10.1111/tbed.13718

Cited by 6 publications

(4 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, a DNA-based vaccine encoding a soluble CD40 ligand (CD40L) and the adjuvant Montanide™ GEL01 (GEL01) activates bovine afferent lymph dendritic cells (ALDCs) in vitro, increasing the expression of MHC II and co-stimulatory molecules [78]. Furthermore, bovine ALDCs were activated (assessed by CD40 up-regulation) by a DNA-based vaccine encoding a truncated BoHV-1 glycoprotein D (pCIgD), either alone or encapsulated in a liposomal formulation containing LPS and MANα1-2MAN-PEG-DOPE (pCIgD-Man-L) [79].…”

Section: Dendritic Cellsmentioning

confidence: 99%

The Cell-Mediated Immune Response against Bovine alphaherpesvirus 1 (BoHV-1) Infection and Vaccination

et al. 2023

View full text Add to dashboard Cite

Bovine Alphaherpesvirus 1 (BoHV-1) is one of the major respiratory pathogens in cattle worldwide. Infection often leads to a compromised host immune response that contributes to the development of the polymicrobial disease known as “bovine respiratory disease”. After an initial transient phase of immunosuppression, cattle recover from the disease. This is due to the development of both innate and adaptive immune responses. With respect to adaptive immunity, both humoral and cell-mediated immunity are required to control infection. Thus, several BoHV-1 vaccines are designed to trigger both branches of the adaptive immune system. In this review, we summarize the current knowledge on cell-mediated immune responses directed against BoHV-1 infection and vaccination.

show abstract

Section: Dendritic Cellsmentioning

confidence: 99%

The Cell-Mediated Immune Response against Bovine alphaherpesvirus 1 (BoHV-1) Infection and Vaccination

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Our work has started with the design of the α1,2-mannobiose nanovaccine platform and its use to formulate a DNA vaccine against BoHV-1 . Since the results were very promising in mice, we proceeded to vaccinate bovines (natural BoHV-1 host) and evaluate the immune response including a viral challenge …”

Section: Discussionmentioning

confidence: 99%

“…Our study was motivated by the limitations of the current approaches for DC targeting and the results obtained in our previous work using a nanovaccine platform, where we have shown the enhanced immune response in vivo of a DNA nanovaccine against BoHV-1 both in mice and bovines when using this platform to formulate and vehicularize the plasmids . In addition, in earlier work, we obtained good preliminary results in vivo using this nanovaccine platform in vehicularizing lipid and protein antigens in a formulation against Brucella ovis, in rams…”

Section: Introductionmentioning

confidence: 99%

Characterization of a Nanovaccine Platform Based on an α1,2-Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells

et al. 2021

Self Cite

View full text Add to dashboard Cite

Dendritic cells serve as the main immune cells that trigger the immune response. We developed a simple and cost-effective nanovaccine platform based on the α1′,2-mannobiose derivative for dendritic cell targeting. In previous work, we have formulated the α1,2-mannobiose-based nanovaccine platform with plasmid DNA and tested it in cattle against BoHV-1 infection. There, we have shown that the dendritic cell targeting using this nanovaccine platform in vivo can boost the immunogenicity, resulting in a long-lasting immunity. In this work, we aim to characterize the α1′,2-mannobiose derivative, which is key in the nanovaccine platform. This DC-targeting strategy takes advantage of the specific receptor known as DC-SIGN and exploits its capacity to bind α1,2-mannobiose that is present at terminal ends of oligosaccharides in certain viruses, bacteria, and other pathogens. The oxidative conjugation of α1′,2-mannobiose to NH2-PEG2kDa-DSPE allowed us to preserve the chemical structure of the non-reducing mannose of the disaccharide and the OH groups and the stereochemistry of all carbons of the reducing mannose involved in the binding to DC-SIGN. Here, we show specific targeting to DC-SIGN of decorated micelles incubated with the Raji/DC-SIGN cell line and uptake of targeted liposomes that took place in human, bovine, mouse, and teleost fish DCs in vitro, by flow cytometry. Specific targeting was found in all cultures, demonstrating a species-non-specific avidity for this ligand, which opens up the possibility of using this nanoplatform to develop new vaccines for various species, including humans.

show abstract

“…Infectious bovine rhinotracheitis virus (IBRV), also called bovine herpesvirus 1 (BoHV-1), is a major viral pathogen of cattle worldwide causing infectious bovine rhinotracheitis (IBR), infectious pustular vulvovaginitis (IPV), and infectious pustular balanoposthitis (IPB) [1] in cattle of all ages and breeds [2,3]. After acute infection, the virus can cause lifelong latent infection [4], and its reactivation, likely induced by certain stressors, leads to virus spread within and among cattle herds.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Antiviral Activity of Ivermectin against Infectious Bovine Rhinotracheitis Virus in Rabbit Model

Wang,

Chen,

Chen

et al. 2023

Animals

View full text Add to dashboard Cite

Infectious bovine rhinotracheitis (IBR) caused by bovine herpes virus 1 (BoHV-1) can lead to enormous economic losses in the cattle industry. Vaccine immunization is preferentially used to decrease its transmission speed and resultant clinical signs, rather than to completely stop viral infection. Therefore, a drug effective in treating IBR is urgently needed. Our previous work demonstrated that ivermectin significantly inhibited viral replication in a cell infection model. This study aimed to investigate its antiviral effects in vivo by using a rabbit infection model. The viral inhibition assay was first used to confirm that ivermectin at low concentrations (6–25 nM) could reduce viral titers (TCID50) significantly (p < 0.001) at 24 h post-infection. In rabbits, ivermectin was administrated with one to three doses, based on the recommended anti-parasite treatment dosage (0.2 mg/kg bodyweight) through subcutaneous injection at different days post-infection in the treated IBRV infection groups, while non-treated infection group was used as the control. The infected rabbits showed hyperthermia and other clinical signs, but the number of high-fever rabbits in the ivermectin treatment groups was significantly lower than that in the non-treated infection group. Furthermore, in ivermectin treatment groups, the cumulative clinical scores correlated negatively with drug doses and positively with delay of administration time post-infection. The overall nasal shedding time in ivermectin-treated groups was two days shorter than the non-treated challenge group. At the same time point, the titer of neutralizing antibodies in the treatment group with triple doses was higher than the other two-dose groups, but the difference between the treatment groups decreased with the delay of drug administration. Correspondingly, the serious extent of lung lesions was negatively related to the dosage, but positively related to the delay of drug administration. The qPCR with tissue homogenates showed that the virus was present in both the lung tissues and trigeminals of the infected rabbits. In conclusion, ivermectin treatment had therapeutic effect by decreasing clinical signs and viral shedding, but could not stop virus proliferation in lung tissues and trigeminals.

show abstract

MANα1‐2MAN decorated liposomes enhance the immunogenicity induced by a DNA vaccine against BoHV‐1

Cited by 6 publications

References 48 publications

The Cell-Mediated Immune Response against Bovine alphaherpesvirus 1 (BoHV-1) Infection and Vaccination

The Cell-Mediated Immune Response against Bovine alphaherpesvirus 1 (BoHV-1) Infection and Vaccination

Characterization of a Nanovaccine Platform Based on an α1,2-Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells

Evaluation of Antiviral Activity of Ivermectin against Infectious Bovine Rhinotracheitis Virus in Rabbit Model

Contact Info

Product

Resources

About